Physician profile
Jason Qualley
NPI 1215432901
$8,598.17
in general payments reported to CMS, 2019-2025
26 companies · $3,568 in 2025
The $3,568 reported for 2025 was more than what 88% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $136 · 2024: $4,894 · 2025: $3,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,521 · Travel and Lodging: $2,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,520.85 |
| Travel and Lodging | $2,077.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,294.58 | 2024-2025 | Proclaim, Eterna, Octrode |
| Boston Scientific Corporation | $1,636.12 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Mml US, INC. | $779.58 | 2025 | Reactiv8 |
| Surgentec | $492.16 | 2024 | Osteoflo |
| Protega Pharmaceutials INC | $413.96 | 2024 | Roxybond |
| Cerapedics INC. | $383.31 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Collegium Pharmaceutical, INC. | $330.06 | 2024-2025 | Xtampza, Belbuca |
| Globus Medical, INC. | $324.60 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $274.79 | 2024 | |
| Medtronic, INC. | $230.94 | 2025 | Inceptiv |
| Foundation Fusion Solutions, LLC | $226.24 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.73 | 2024-2025 | Relistor |
| Vertos Medical, INC. | $161.93 | 2024 | Mild Device Kit |
| Nevro Corp. | $134.49 | 2024 | Senza |
| Nalu Medical, INC. | $125.00 | 2024 | Nalu Neurostimulation System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $110.96 | 2024 | Horizant |
| Abbvie INC. | $105.01 | 2024 | |
| Spr Therapeutics, INC | $79.03 | 2024 | Sprint Pns System |
| Si-Bone, INC. | $62.91 | 2024-2025 | |
| Lilly USA, LLC | $59.85 | 2024 | Reyvow, Emgality |
| Saluda Medical Americas, INC. | $51.90 | 2025 | Evoke |
| Valinor Pharma, LLC | $29.40 | 2025 | Movantik |
| Pfizer INC. | $26.23 | 2024 | |
| Curonix LLC | $19.41 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Merck Sharp & Dohme LLC | $16.78 | 2023 | Verquvo, Steglatro |
| Idorsia Pharmaceuticals US INC | $13.20 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Qualley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.